Knocking out Caveolin-1 in the A549 lung cancer cell line ultimately increases the sensitivity of lung cancer to cisplatin-induced apoptosis therapy by inhibiting Parkin-related mitophagy and amplifying cisplatin-induced mitochondria-related apoptotic signaling (Liu et al., 2020). Here, PRKN is linked to lung carcinoma.